Treatment-Related Adverse Events are Ordered by All-Grade Incidence. Each Patient is Represented by the Maximum Grade of Toxicity Experienced for Each Subcategory. No Grade 4–5 Toxicities Were Seen.
| Adverse Event . | Grades 1–2 . | Grade 3 . | Total (%) . |
|---|---|---|---|
| Metabolism disorder | 11 (85%) | 1 (8.3%) | 12 (92%) |
| Hyperphosphatemia | 9 (69%) | 0 (0%) | 9 (69%) |
| Other metabolism disorder | 5 (38%) | 1 (8%) a | 6 (46%) |
| Other disorders | 10 (77%) | 2 (15%) | 12 (92%) |
| Nail changes/onycholysis | 8 (62%) | 1 (8%) | 9 (69%) |
| Stomatitis | 6 (46%) | 1 (8%) | 7 (54%) |
| Dry skin | 6 (46%) | 0 (0%) | 6 (46%) |
| Fatigue | 4 (31%) | 0 (0%) | 4 (31%) |
| Alopecia | 3 (23%) | 0 (0%) | 3 (23%) |
| Infection | 1 (8%) | 0 (0%) | 1 (8%) |
| Other disorder | 7 (53%) | 1 (8%) b | 8 (62%) |
| Eye disorder | 10 (77%) | 0 (0%) | 10 (77%) |
| Retinal detachment | 6 (46%) | 0 (0%) | 6 (46%) |
| Blurred vision | 1 (8%) | 0 (0%) | 1 (%) |
| Other eye disorders | 6 (46%) | 0 (0%) | 6 (46%) |
| Hematologic disorder | 5 (38%) | 1 (8%) | 6 (46%) |
| Thrombopenia | 2 (15%) | 0 (0%) | 2 (15%) |
| Leukopenia | 2 (15%) | 0 (0%) | 2 (15%) |
| Neutropenia | 1 (8%) | 0 (0%) | 1 (8%) |
| Anemia | 1 (8%) | 0 (0%) | 1 (8%) |
| Other hematologic disorder | 3 (23%) | 1 (8%) c | 4 (31%) |
| Renal disorder | 2 (15%) | 0 (0%) | 2 (15%) |
| Proteinuria | 1 (8%) | 0 (0%) | 1 (8%) |
| Other renal disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Cardiac disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Other cardiac disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Total | 13 (100%) | 3 (23%) | 13 (100%) |
| Adverse Event . | Grades 1–2 . | Grade 3 . | Total (%) . |
|---|---|---|---|
| Metabolism disorder | 11 (85%) | 1 (8.3%) | 12 (92%) |
| Hyperphosphatemia | 9 (69%) | 0 (0%) | 9 (69%) |
| Other metabolism disorder | 5 (38%) | 1 (8%) a | 6 (46%) |
| Other disorders | 10 (77%) | 2 (15%) | 12 (92%) |
| Nail changes/onycholysis | 8 (62%) | 1 (8%) | 9 (69%) |
| Stomatitis | 6 (46%) | 1 (8%) | 7 (54%) |
| Dry skin | 6 (46%) | 0 (0%) | 6 (46%) |
| Fatigue | 4 (31%) | 0 (0%) | 4 (31%) |
| Alopecia | 3 (23%) | 0 (0%) | 3 (23%) |
| Infection | 1 (8%) | 0 (0%) | 1 (8%) |
| Other disorder | 7 (53%) | 1 (8%) b | 8 (62%) |
| Eye disorder | 10 (77%) | 0 (0%) | 10 (77%) |
| Retinal detachment | 6 (46%) | 0 (0%) | 6 (46%) |
| Blurred vision | 1 (8%) | 0 (0%) | 1 (%) |
| Other eye disorders | 6 (46%) | 0 (0%) | 6 (46%) |
| Hematologic disorder | 5 (38%) | 1 (8%) | 6 (46%) |
| Thrombopenia | 2 (15%) | 0 (0%) | 2 (15%) |
| Leukopenia | 2 (15%) | 0 (0%) | 2 (15%) |
| Neutropenia | 1 (8%) | 0 (0%) | 1 (8%) |
| Anemia | 1 (8%) | 0 (0%) | 1 (8%) |
| Other hematologic disorder | 3 (23%) | 1 (8%) c | 4 (31%) |
| Renal disorder | 2 (15%) | 0 (0%) | 2 (15%) |
| Proteinuria | 1 (8%) | 0 (0%) | 1 (8%) |
| Other renal disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Cardiac disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Other cardiac disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Total | 13 (100%) | 3 (23%) | 13 (100%) |
aHyperglycemia; bAlanine aminotransferase increase; cLymphopenia.
Treatment-Related Adverse Events are Ordered by All-Grade Incidence. Each Patient is Represented by the Maximum Grade of Toxicity Experienced for Each Subcategory. No Grade 4–5 Toxicities Were Seen.
| Adverse Event . | Grades 1–2 . | Grade 3 . | Total (%) . |
|---|---|---|---|
| Metabolism disorder | 11 (85%) | 1 (8.3%) | 12 (92%) |
| Hyperphosphatemia | 9 (69%) | 0 (0%) | 9 (69%) |
| Other metabolism disorder | 5 (38%) | 1 (8%) a | 6 (46%) |
| Other disorders | 10 (77%) | 2 (15%) | 12 (92%) |
| Nail changes/onycholysis | 8 (62%) | 1 (8%) | 9 (69%) |
| Stomatitis | 6 (46%) | 1 (8%) | 7 (54%) |
| Dry skin | 6 (46%) | 0 (0%) | 6 (46%) |
| Fatigue | 4 (31%) | 0 (0%) | 4 (31%) |
| Alopecia | 3 (23%) | 0 (0%) | 3 (23%) |
| Infection | 1 (8%) | 0 (0%) | 1 (8%) |
| Other disorder | 7 (53%) | 1 (8%) b | 8 (62%) |
| Eye disorder | 10 (77%) | 0 (0%) | 10 (77%) |
| Retinal detachment | 6 (46%) | 0 (0%) | 6 (46%) |
| Blurred vision | 1 (8%) | 0 (0%) | 1 (%) |
| Other eye disorders | 6 (46%) | 0 (0%) | 6 (46%) |
| Hematologic disorder | 5 (38%) | 1 (8%) | 6 (46%) |
| Thrombopenia | 2 (15%) | 0 (0%) | 2 (15%) |
| Leukopenia | 2 (15%) | 0 (0%) | 2 (15%) |
| Neutropenia | 1 (8%) | 0 (0%) | 1 (8%) |
| Anemia | 1 (8%) | 0 (0%) | 1 (8%) |
| Other hematologic disorder | 3 (23%) | 1 (8%) c | 4 (31%) |
| Renal disorder | 2 (15%) | 0 (0%) | 2 (15%) |
| Proteinuria | 1 (8%) | 0 (0%) | 1 (8%) |
| Other renal disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Cardiac disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Other cardiac disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Total | 13 (100%) | 3 (23%) | 13 (100%) |
| Adverse Event . | Grades 1–2 . | Grade 3 . | Total (%) . |
|---|---|---|---|
| Metabolism disorder | 11 (85%) | 1 (8.3%) | 12 (92%) |
| Hyperphosphatemia | 9 (69%) | 0 (0%) | 9 (69%) |
| Other metabolism disorder | 5 (38%) | 1 (8%) a | 6 (46%) |
| Other disorders | 10 (77%) | 2 (15%) | 12 (92%) |
| Nail changes/onycholysis | 8 (62%) | 1 (8%) | 9 (69%) |
| Stomatitis | 6 (46%) | 1 (8%) | 7 (54%) |
| Dry skin | 6 (46%) | 0 (0%) | 6 (46%) |
| Fatigue | 4 (31%) | 0 (0%) | 4 (31%) |
| Alopecia | 3 (23%) | 0 (0%) | 3 (23%) |
| Infection | 1 (8%) | 0 (0%) | 1 (8%) |
| Other disorder | 7 (53%) | 1 (8%) b | 8 (62%) |
| Eye disorder | 10 (77%) | 0 (0%) | 10 (77%) |
| Retinal detachment | 6 (46%) | 0 (0%) | 6 (46%) |
| Blurred vision | 1 (8%) | 0 (0%) | 1 (%) |
| Other eye disorders | 6 (46%) | 0 (0%) | 6 (46%) |
| Hematologic disorder | 5 (38%) | 1 (8%) | 6 (46%) |
| Thrombopenia | 2 (15%) | 0 (0%) | 2 (15%) |
| Leukopenia | 2 (15%) | 0 (0%) | 2 (15%) |
| Neutropenia | 1 (8%) | 0 (0%) | 1 (8%) |
| Anemia | 1 (8%) | 0 (0%) | 1 (8%) |
| Other hematologic disorder | 3 (23%) | 1 (8%) c | 4 (31%) |
| Renal disorder | 2 (15%) | 0 (0%) | 2 (15%) |
| Proteinuria | 1 (8%) | 0 (0%) | 1 (8%) |
| Other renal disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Cardiac disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Other cardiac disorder | 1 (8%) | 0 (0%) | 1 (8%) |
| Total | 13 (100%) | 3 (23%) | 13 (100%) |
aHyperglycemia; bAlanine aminotransferase increase; cLymphopenia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
